Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma.

International journal of cancer - 15 Aug 2026

Stoff Ronen, Bilgin Gokce Belge, Nikanpour Yalda, Johnson Geoffrey B, Kipp Benjamin R, Zahrieh David M, Geiersbach Katherine B, Block Matthew S, Markovic Svetomir N

Abstract excerpt

Circulating tumor DNA (ctDNA) as a liquid biopsy is an emerging tool used for diagnosis and disease monitoring, yet not all tumors shed DNA equally, thus currently limiting the clinical applicability of this tool. Our institution has developed and validated a droplet digital Polymerase Chain Reaction (ddPCR) ctDNA test for BRAF V600 mutation. We collected data on all BRAF mutated melanoma patients tested with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Melanoma

Share to Positron Emission Tomography Computed Tomography

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42011804
DOI: 10.1002/ijc.70514
PMCID: PMC13284622

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma.PMID 42011804Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.Semantic proximity Read ↗

Ultra-rapid droplet digital PCR enables intraoperative tumor quantification.Semantic proximity Read ↗

Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.Semantic proximity Read ↗

Ultra-Rapid Droplet Digital PCR Enables Intraoperative Tumor QuantificationSemantic proximity Read ↗

Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content.Semantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays.Semantic proximity Read ↗

Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.Semantic proximity Read ↗

Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.Semantic proximity Read ↗

Guiding treatment and clinical management of patients with CNS lymphomas by minimal-invasive detection of circulating tumor DNA in cerebrospinal fluidSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.